Physician profile
Abigail Orta
NPI 1285374645
$8,757.14
in general payments reported to CMS, 2019-2025
30 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.98 · 2022: $1,428 · 2023: $2,499 · 2024: $2,435 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,314.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,022.46 | 2022-2025 | Onyx Frontier, Symplicity G3, Linq II |
| Cvrx, INC. | $539.76 | 2022-2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $443.01 | 2022-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $420.95 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $371.22 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $370.47 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $270.98 | 2023 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $258.04 | 2022-2024 | |
| Amgen INC. | $241.36 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $155.58 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.36 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $57.71 | 2025 | Opsumit |
| Scpharmaceuticals INC. | $54.60 | 2024-2025 | |
| Esperion Therapeutics, INC. | $52.31 | 2025 | Nexletol |
| Vital Connect, INC | $38.64 | 2022-2024 | Vitalpatch Rtm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $38.45 | 2024 | Assure Wcd |
| Novo Nordisk INC | $38.44 | 2022-2025 | Wegovy |
| Daiichi Sankyo INC. | $29.74 | 2023 | Injectafer |
| Shockwave Medical, INC | $25.19 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inspire Medical Systems, INC. | $24.55 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $23.63 | 2023 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $21.09 | 2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $21.07 | 2023 | Xarelto |
| W. L. Gore & Associates, INC. | $19.30 | 2022 | |
| Chiesi USA, INC. | $18.14 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $17.78 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $17.55 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| United Therapeutics Corporation | $17.54 | 2023 | Tyvaso |
| Kiniksa Pharmaceuticals, LTD. | $15.63 | 2023 | Arcalyst |
| Boston Scientific Corporation | $14.59 | 2024 | Lux-Dx Insertable Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Orta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.